Sagent Pharma sets up research center in China

US specialty drug firm Sagent Pharmaceuticals (Nasdaq: SGNT), which has a specific emphasis on the injectable market, says it has launched its National Research Center in Chengdu, China.

Based in Chengdu's Bio-Technology Park, the NRC will focus on process and method development of technically challenging specialty injectable pharmaceuticals. Staffed with an international team of experienced research scientists, the center will initially focus on developing both liquid and lypholization products for Sagent China Pharmaceuticals (SCP), Sagent's Food and Drug Administration-inspected manufacturing facility, also located in Chengdu.

"Building a first class development center in support of our manufacturing capabilities is a natural next step in our strategic evolution," said Jeffrey Yordon, chief executive and chairman of Sagent, DDING: "The NRC is equipped with state-of-the-art equipment and staffed with a team of global experts in specialty injectable development. We are proud of the progress of our team in China and pleased to provide increased support for the rapid development of additional products to be manufactured at SCP."